Wesley R Campbell1, Ping Li2,3, Timothy J Whitman4, Dana M Blyth5, Elizabeth R Schnaubelt6, Katrin Mende2,3,5, David R Tribble2. 1. 1 Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, Maryland. 2. 2 Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences , Bethesda, Maryland. 3. 3 Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. , Bethesda, Maryland. 4. 4 Walter Reed National Military Medical Center , Bethesda, Maryland. 5. 5 San Antonio Military Medical Center , Fort Sam Houston, Texas. 6. 6 Landstuhl Regional Medical Center , Landstuhl, Germany.
Abstract
BACKGROUND: The contribution of multi-drug-resistant gram-negative bacilli infections (MDRGN-I) in patients with trauma is not well described. We present characteristics of MDRGN-Is among military personnel with deployment-related trauma (2009-2014). PATIENTS AND METHODS: Data from the Trauma Infectious Disease Outcomes Study were assessed for infectious outcomes and microbial recovery. Infections were classified using standardized definitions. Gram-negative bacilli were defined as multi-drug-resistant if they showed resistance to ≥3 antibiotic classes or were producers of extended-spectrum β-lactamase or carbapenemases. RESULTS: Among 2,699 patients admitted to participating U.S. hospitals, 913 (33.8%) experienced ≥1 infection event, of which 245 (26.8%) had a MDRGN-I. There were 543 MDRGN-I events (24.6% of unique 2,210 infections) with Escherichia coli (48.3%), Acinetobacter spp. (38.6%), and Klebsiella pneumoniae (8.4%) as the most common MDRGN isolates. Incidence of MDRGN-I was 9.1% (95% confidence interval [CI]: 8.0-10.2). Median time to MDRGN-I event was seven days with 75% occurring within 13 days post-trauma. Patients with MDRGN-Is had a greater proportion of blast injuries (84.1% vs. 62.5%; p < 0.0001), traumatic amputations (57.5% vs. 16.3%; p < 0.0001), and higher injury severity (82.0% had injury severity score ≥25 vs. 33.7%; p < 0.0001) compared with patients with either no infections or non-MDRGN-Is. Furthermore, MDRGN-I patients were more frequently admitted to the intensive care unit (90.5% vs. 48.5%; p < 0.0001), colonized with a MDRGN before infection (58.0% vs. 14.7%; p < 0.0001), and required mechanical ventilation (78.0% vs. 28.8% p < 0.0001). Antibiotic exposure before the MDRGN-I event was significantly higher across antibiotic classes except first generation cephalosporins and tetracyclines, which were very commonly used with all patients. Regarding outcomes, patients with MDRGN-Is had a longer length of hospitalization than the comparator group (53 vs. 18 days; p < 0.0001). CONCLUSIONS: We found a high rate of MDRGN-I in our population characterized by longer hospitalization and greater injury severity. These findings inform treatment and infection control decisions in the trauma patient population.
BACKGROUND: The contribution of multi-drug-resistant gram-negative bacilli infections (MDRGN-I) in patients with trauma is not well described. We present characteristics of MDRGN-Is among military personnel with deployment-related trauma (2009-2014). PATIENTS AND METHODS: Data from the Trauma Infectious Disease Outcomes Study were assessed for infectious outcomes and microbial recovery. Infections were classified using standardized definitions. Gram-negative bacilli were defined as multi-drug-resistant if they showed resistance to ≥3 antibiotic classes or were producers of extended-spectrum β-lactamase or carbapenemases. RESULTS: Among 2,699 patients admitted to participating U.S. hospitals, 913 (33.8%) experienced ≥1 infection event, of which 245 (26.8%) had a MDRGN-I. There were 543 MDRGN-I events (24.6% of unique 2,210 infections) with Escherichia coli (48.3%), Acinetobacter spp. (38.6%), and Klebsiella pneumoniae (8.4%) as the most common MDRGN isolates. Incidence of MDRGN-I was 9.1% (95% confidence interval [CI]: 8.0-10.2). Median time to MDRGN-I event was seven days with 75% occurring within 13 days post-trauma. Patients with MDRGN-Is had a greater proportion of blast injuries (84.1% vs. 62.5%; p < 0.0001), traumatic amputations (57.5% vs. 16.3%; p < 0.0001), and higher injury severity (82.0% had injury severity score ≥25 vs. 33.7%; p < 0.0001) compared with patients with either no infections or non-MDRGN-Is. Furthermore, MDRGN-Ipatients were more frequently admitted to the intensive care unit (90.5% vs. 48.5%; p < 0.0001), colonized with a MDRGN before infection (58.0% vs. 14.7%; p < 0.0001), and required mechanical ventilation (78.0% vs. 28.8% p < 0.0001). Antibiotic exposure before the MDRGN-I event was significantly higher across antibiotic classes except first generation cephalosporins and tetracyclines, which were very commonly used with all patients. Regarding outcomes, patients with MDRGN-Is had a longer length of hospitalization than the comparator group (53 vs. 18 days; p < 0.0001). CONCLUSIONS: We found a high rate of MDRGN-I in our population characterized by longer hospitalization and greater injury severity. These findings inform treatment and infection control decisions in the traumapatient population.
Authors: Duane R Hospenthal; Clinton K Murray; Romney C Andersen; R Bryan Bell; Jason H Calhoun; Leopoldo C Cancio; John M Cho; Kevin K Chung; Jon C Clasper; Marcus H Colyer; Nicholas G Conger; George P Costanzo; Helen K Crouch; Thomas K Curry; Laurie C D'Avignon; Warren C Dorlac; James R Dunne; Brian J Eastridge; James R Ficke; Mark E Fleming; Michael A Forgione; Andrew D Green; Robert G Hale; David K Hayes; John B Holcomb; Joseph R Hsu; Kent E Kester; Gregory J Martin; Leon E Moores; William T Obremskey; Kyle Petersen; Evan M Renz; Jeffrey R Saffle; Joseph S Solomkin; Deena E Sutter; David R Tribble; Joseph C Wenke; Timothy J Whitman; Andrew R Wiesen; Glenn W Wortmann Journal: J Trauma Date: 2011-08
Authors: Duane R Hospenthal; Helen K Crouch; Judith F English; Fluryanne Leach; Jane Pool; Nicholas G Conger; Timothy J Whitman; Glenn W Wortmann; Janelle L Robertson; Clinton K Murray Journal: J Trauma Date: 2011-07
Authors: Carrie Lee Teicher; Jean-Baptiste Ronat; Rasheed M Fakhri; Mohamed Basel; Amy S Labar; Patrick Herard; Richard A Murphy Journal: Emerg Infect Dis Date: 2014-11 Impact factor: 6.883
Authors: Sarah E Schall; Ping Li; Timothy J Whitman; Joseph L Petfield; David R Tribble; Dana M Blyth Journal: Infect Control Hosp Epidemiol Date: 2020-06-30 Impact factor: 3.254
Authors: Laveta Stewart; Ping Li; Maj Dana M Blyth; Wesley R Campbell; Joseph L Petfield; Margot Krauss; Lauren Greenberg; David R Tribble Journal: Mil Med Date: 2020-01-07 Impact factor: 1.437
Authors: David R Tribble; Clinton K Murray; Bradley A Lloyd; Anuradha Ganesan; Katrin Mende; Dana M Blyth; Joseph L Petfield; Jay McDonald Journal: Mil Med Date: 2019-11-01 Impact factor: 1.437
Authors: Rae A Heitkamp; Ping Li; Katrin Mende; Samandra T Demons; David R Tribble; Stuart D Tyner Journal: Surg Infect (Larchmt) Date: 2017-12-20 Impact factor: 2.150
Authors: Shannon L McCarthy; Laveta Stewart; Faraz Shaikh; Clinton K Murray; David R Tribble; Dana M Blyth Journal: J Intensive Care Med Date: 2022-02-16 Impact factor: 2.889
Authors: Katrin Mende; Kevin S Akers; Stuart D Tyner; Jason W Bennett; Mark P Simons; Dana M Blyth; Ping Li; Laveta Stewart; David R Tribble Journal: Mil Med Date: 2022-05-04 Impact factor: 1.563
Authors: Shane B Patterson; Katrin Mende; Ping Li; Dan Lu; M Leigh Carson; Clinton K Murray; David R Tribble; Dana M Blyth Journal: Diagn Microbiol Infect Dis Date: 2019-11-23 Impact factor: 2.803
Authors: Joseph M Yabes; Laveta Stewart; Faraz Shaikh; Paul M Robben; Joseph L Petfield; Anuradha Ganesan; Wesley R Campbell; David R Tribble; Dana M Blyth Journal: J Intensive Care Med Date: 2020-06-08 Impact factor: 2.889
Authors: Mary B Ford; Katrin Mende; Susan J Kaiser; Miriam L Beckius; Dan Lu; Jason Stam; Ping Li; Laveta Stewart; David R Tribble; Dana M Blyth Journal: Mil Med Date: 2022-03-28 Impact factor: 1.563